Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM study of UCART19 in relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia
jRCT2013190002Phase 1Completed
- Sponsor
- Nihon Servier
- Start
- Feb 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 1, open-label, single-arm trial of UCART19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Nihon Servier. Primary endpoint: Dose-limiting toxicities. Started Feb 2020; status: completed.
02
Drugs
UCART19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT2013190002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013190002.